

Re: Identification of preferred continuous glucose monitoring sensors

19th July 2024

Dear Colleagues,

The Health Service Executive-Medicines Management Programme (HSE-MMP) has completed an evaluation to identify preferred continuous glucose monitoring (CGM) sensors with associated systems, as part of the MMP's remit to support safe, effective and cost-effective prescribing.

The evaluation process was undertaken in accordance with the *MMP roadmap for the identification of preferred continuous glucose monitoring sensor(s) with associated system(s)*, and included a consultation period for submissions from stakeholders. The evaluation report is available on the MMP website (www.hse.ie/mmp) in the section entitled *Glucose monitoring*.

The MMP recommends the following preferred CGM sensors (List A):

Preferred CGM sensors – List A		
CGM sensor	Reimbursement code	Pack size
Freestyle Libre 2	85581	1
Dexcom ONE+	97636	1

The MMP recommends that healthcare professionals should give due consideration to the use of a preferred CGM sensor with associated system, for people with diabetes* requiring CGM who are not insulin pump users, when:

- First initiating CGM
- Continuing CGM upon review
- Changing CGM sensor with associated system

In 2023, total expenditure on CGM sensors under the Community Drug Schemes was approximately €55.7 million. Utilisation of preferred CGM sensors for appropriate patients will realise efficiencies in this area of expenditure. Given the significant financial challenges facing the health service, it is vital that the prescribing of CGM sensors is optimised. The MMP will continue to monitor the expenditure in this area and the uptake of the preferred CGM sensors to ensure that efficiencies are fully realised.

Please find enclosed a preferred CGM sensor poster outlining the preferred CGM sensors, notable features and other useful information about these products. Further information on the preferred CGM sensors is available on the MMP website (www.hse.ie/mmp) in the section entitled *Glucose monitoring*.

My thanks for your ongoing support in promoting safe, effective and cost-effective prescribing.

With best wishes,



Professor Michael Barry, National Clinical Lead, Medicines Management Programme www.hse.ie/mmp

*Reimbursement is supported in accordance with Primary Care Reimbursement Service circular 033/23 Continuous Glucose Monitoring (CGM) Reimbursement Application System.